Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.

Harada K, Nakato K, Yarimizu J, Yamazaki M, Morita M, Takahashi S, Aota M, Saita K, Doihara H, Sato Y, Yamaji T, Ni K, Matsuoka N.

Eur J Pharmacol. 2012 Jun 15;685(1-3):59-69. doi: 10.1016/j.ejphar.2012.04.013. Epub 2012 Apr 20.

PMID:
22542656
2.

Efficacy of a glycine transporter 1 inhibitor TASP0315003 in animal models of cognitive dysfunction and negative symptoms of schizophrenia.

Chaki S, Shimazaki T, Karasawa J, Aoki T, Kaku A, Iijima M, Kambe D, Yamamoto S, Kawakita Y, Shibata T, Abe K, Okubo T, Sekiguchi Y, Okuyama S.

Psychopharmacology (Berl). 2015 Aug;232(15):2849-61. doi: 10.1007/s00213-015-3920-3. Epub 2015 Apr 15.

PMID:
25869273
3.

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.

Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C, Alonso R, Vigé X, Biton B, Steinberg R, Sevrin M, Oury-Donat F, George P, Bergis O, Griebel G, Avenet P, Scatton B.

Pharmacol Biochem Behav. 2008 Nov;91(1):47-58. doi: 10.1016/j.pbb.2008.06.009. Epub 2008 Jun 24.

PMID:
18621075
4.

Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1).

Manahan-Vaughan D, Wildförster V, Thomsen C.

Eur J Neurosci. 2008 Oct;28(7):1342-50. doi: 10.1111/j.1460-9568.2008.06433.x.

PMID:
18973561
5.

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.

Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A, Voltz C, Boulay D, Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vigé X, Biton B, Steinberg R, Françon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrié P, Scatton B.

Neuropsychopharmacology. 2005 Nov;30(11):1963-85.

6.

ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia.

Yamazaki M, Harada K, Yamamoto N, Yarimizu J, Okabe M, Shimada T, Ni K, Matsuoka N.

Eur Neuropsychopharmacol. 2014 Oct;24(10):1698-708. doi: 10.1016/j.euroneuro.2014.07.009. Epub 2014 Jul 27.

7.

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.

Black MD, Varty GB, Arad M, Barak S, De Levie A, Boulay D, Pichat P, Griebel G, Weiner I.

Psychopharmacology (Berl). 2009 Jan;202(1-3):385-96. doi: 10.1007/s00213-008-1289-2. Epub 2008 Aug 16.

PMID:
18709358
8.

D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats.

Karasawa J, Hashimoto K, Chaki S.

Behav Brain Res. 2008 Jan 10;186(1):78-83. Epub 2007 Aug 2.

PMID:
17854919
9.

1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat.

Pietraszek M, Michaluk J, Romańska I, Wasik A, Gołembiowska K, Antkiewicz-Michaluk L.

Neurotox Res. 2009 Nov;16(4):390-407. doi: 10.1007/s12640-009-9097-y. Epub 2009 Aug 1.

PMID:
19649683
10.

Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.

Yee BK, Balic E, Singer P, Schwerdel C, Grampp T, Gabernet L, Knuesel I, Benke D, Feldon J, Mohler H, Boison D.

J Neurosci. 2006 Mar 22;26(12):3169-81.

11.

Synthesis and biological evaluation of 3-biphenyl-4-yl-4-phenyl-4H-1,2,4-triazoles as novel glycine transporter 1 inhibitors.

Sugane T, Tobe T, Hamaguchi W, Shimada I, Maeno K, Miyata J, Suzuki T, Kimizuka T, Kohara A, Morita T, Doihara H, Saita K, Aota M, Furutani M, Shimada Y, Hamada N, Sakamoto S, Tsukamoto S.

J Med Chem. 2011 Jan 13;54(1):387-91. doi: 10.1021/jm101031u. Epub 2010 Dec 9. Erratum in: J Med Chem. 2011 Jan 13;54(1):391.

PMID:
21141920
12.

Atropisomeric 4-phenyl-4H-1,2,4-triazoles as selective glycine transporter 1 inhibitors.

Sugane T, Tobe T, Hamaguchi W, Shimada I, Maeno K, Miyata J, Suzuki T, Kimizuka T, Sakamoto S, Tsukamoto S.

J Med Chem. 2013 Jul 25;56(14):5744-56. doi: 10.1021/jm400383w. Epub 2013 Jul 9.

PMID:
23837744
13.

Inhibitors of GlyT1 affect glycine transport via discrete binding sites.

Mezler M, Hornberger W, Mueller R, Schmidt M, Amberg W, Braje W, Ochse M, Schoemaker H, Behl B.

Mol Pharmacol. 2008 Dec;74(6):1705-15. doi: 10.1124/mol.108.049312. Epub 2008 Sep 24. Erratum in: Mol Pharmacol. 2009 Jan;75(1):258.. Amberg, Martin Schmidt Willi [corrected to Schmidt, Martin]; Amberg, Martin Schmidt Willi [corrected to Amberg, Willi].

14.

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the glycine transporter-1 inhibitor NFPS and D-serine.

Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M.

Eur Neuropsychopharmacol. 2008 Jun;18(6):414-21. Epub 2007 Sep 4.

PMID:
17804206
15.

Inhibition of glycine transporter 1 attenuates nicotine- but not food-induced cue-potentiated reinstatement for a response previously paired with sucrose.

Uslaner JM, Drott JT, Sharik SS, Theberge CR, Sur C, Zeng Z, Williams DL, Hutson PH.

Behav Brain Res. 2010 Feb 11;207(1):37-43. doi: 10.1016/j.bbr.2009.09.035. Epub 2009 Sep 30.

PMID:
19799936
16.

Effects of a glycine transporter-1 inhibitor and D-serine on MK-801-induced immobility in the forced swimming test in rats.

Kawaura K, Koike H, Kinoshita K, Kambe D, Kaku A, Karasawa J, Chaki S, Hikichi H.

Behav Brain Res. 2015 Feb 1;278:186-92. doi: 10.1016/j.bbr.2014.09.046. Epub 2014 Oct 6.

PMID:
25300471
17.

Synthesis and characterization of [¹²⁵I]2-iodo N-[(S)-{(S)-1-methylpiperidin-2-yl}(phenyl)methyl]3-trifluoromethyl-benzamide as novel imaging probe for glycine transporter 1.

Fuchigami T, Haratake M, Magata Y, Haradahira T, Nakayama M.

Bioorg Med Chem. 2011 Nov 1;19(21):6245-53. doi: 10.1016/j.bmc.2011.09.010. Epub 2011 Sep 10.

PMID:
21975065
18.

SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents.

Griebel G, Pichat P, Pruniaux MP, Beeské S, Lopez-Grancha M, Genet E, Terranova JP, Castro A, Sánchez JA, Black M, Varty GB, Weiner I, Arad M, Barak S, De Levie A, Guillot E.

Pharmacol Biochem Behav. 2012 Aug;102(2):203-14. doi: 10.1016/j.pbb.2012.04.004. Epub 2012 Apr 21.

19.

SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents.

de Bruin NM, Prickaerts J, Lange JH, Akkerman S, Andriambeloson E, de Haan M, Wijnen J, van Drimmelen M, Hissink E, Heijink L, Kruse CG.

Neurobiol Learn Mem. 2010 May;93(4):522-31. doi: 10.1016/j.nlm.2010.01.010. Epub 2010 Feb 2.

PMID:
20132903
20.

Supplemental Content

Support Center